Literature DB >> 15351862

Modulation of VEGF-induced endothelial cell cycle protein expression through cyclic AMP hydrolysis by PDE2 and PDE4.

Laure Favot1, Thérèse Keravis, Claire Lugnier.   

Abstract

Endothelial cell proliferation in response to VEGF plays an important role in physiological and pathological angiogenesis. The role of PDE2 and PDE4 in VEGF-induced proliferation in HUVEC was investigated: 1) VEGF increased cAMP-hydrolytic activity by up-regulating the expression of PDE2 and PDE4 isozymes; 2) VEGF increased progression in cell cycle with an increase in p42/p44 MAP kinase, cyclin A and cyclin D1 expressions and with a decrease in p21 waf1/cip1 and p27 kip1 expressions; 3) EHNA (20 micro M), a selective PDE2 inhibitor, RP73401 (10 micro M), a selective PDE4 inhibitor blocked the VEGF-induced increase in p42/p44 MAP kinase expression; 4) RP73401, but not EHNA, blocked the VEGF-induced increase in cyclin A and decrease in p27 kip1 expressions; 5) EHNA, contrary to RP73401, enhanced the VEGF-induced increase of cyclin A and decrease of p27 kip1. 6) EHNA and RP73401 together blocked the VEGF-induced increase in cyclin D1 and decrease in p21 waf1/cip1 expressions; 7) Inhibition of VEGF-upregulated PDE2 and PDE4 reversed the VEGF-induced alterations in cell cycle protein expression, bringing back endothelial cells to a non-proliferating status. Consequently, PDE2 and PDE4 inhibitions were able to inhibit VEGF-induced endothelial cell proliferation by restoring cell cycle key protein expression, and might thus be useful in excessive angiogenesis. Furthermore, the differences between PDE2 and PDE4 effects may suggest compartmentalized effects.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15351862     DOI: 10.1160/TH03-12-0768

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  12 in total

Review 1.  Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments.

Authors:  Thérèse Keravis; Claire Lugnier
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

2.  Phosphodiesterase 4D and 5-lipoxygenase activating protein in ischemic stroke.

Authors:  James F Meschia; Thomas G Brott; Robert D Brown; Richard Crook; Bradford B Worrall; Brett Kissela; W Mark Brown; Stephen S Rich; L Douglas Case; E Whitney Evans; Stephen Hague; Andrew Singleton; John Hardy
Journal:  Ann Neurol       Date:  2005-09       Impact factor: 10.422

3.  Inhibitory effects of Rap1GAP overexpression on proliferation and migration of endothelial cells via ERK and Akt pathways.

Authors:  Wenyi Li; Bi Jin; Lynn A Cornelius; Bin Zhou; Xiaoyang Fu; Dan Shang; Hong Zheng
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-12-16

Review 4.  Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiac hypertrophy and heart failure.

Authors:  Rima Kamel; Jérôme Leroy; Grégoire Vandecasteele; Rodolphe Fischmeister
Journal:  Nat Rev Cardiol       Date:  2022-09-01       Impact factor: 49.421

Review 5.  Phosphodiesterase 4 inhibitors have wide-ranging activity in B-cell malignancies.

Authors:  Jeffrey D Cooney; Ricardo C T Aguiar
Journal:  Blood       Date:  2016-10-18       Impact factor: 22.113

6.  PDEs1-5 activity and expression in tissues of cirrhotic rats reveal a role for aortic PDE3 in NO desensitization.

Authors:  Rima Tahseldar-Roumieh; Thérèse Keravis; Suha Maarouf; Hélène Justiniano; Ramzi Sabra; Claire Lugnier
Journal:  Int J Exp Pathol       Date:  2009-09-15       Impact factor: 1.925

7.  Short-term or long-term treatments with a phosphodiesterase-4 (PDE4) inhibitor result in opposing agonist-induced Ca(2+) responses in endothelial cells.

Authors:  M Campos-Toimil; T Keravis; F Orallo; K Takeda; C Lugnier
Journal:  Br J Pharmacol       Date:  2008-03-03       Impact factor: 8.739

8.  Delphinidin Inhibits Tumor Growth by Acting on VEGF Signalling in Endothelial Cells.

Authors:  Thérèse Keravis; Laure Favot; Abdurrazag A Abusnina; Anita Anton; Hélène Justiniano; Raffaella Soleti; Eid Alabed Alibrahim; Gilles Simard; Ramaroson Andriantsitohaina; Claire Lugnier
Journal:  PLoS One       Date:  2015-12-22       Impact factor: 3.240

9.  Characterization of phosphodiesterase 2A in human malignant melanoma PMP cells.

Authors:  Hiroshi Morita; Taku Murata; Kasumi Shimizu; Kenya Okumura; Madoka Inui; Toshiro Tagawa
Journal:  Oncol Rep       Date:  2013-01-31       Impact factor: 3.906

10.  Orphan nuclear receptor TR3/Nur77 regulates VEGF-A-induced angiogenesis through its transcriptional activity.

Authors:  Huiyan Zeng; Liuliang Qin; Dezheng Zhao; Xiaolian Tan; Eleanor J Manseau; Mien Van Hoang; Donald R Senger; Lawrence F Brown; Janice A Nagy; Harold F Dvorak
Journal:  J Exp Med       Date:  2006-03-06       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.